jrnl3206

Publication Venue For

  • 2,4-Diamino pteridine mustard: A new active-site-directed anticancer agent.  VOL. 26. 1985
  • Action of retinoic acid on the expression of the transformed phenotype in Syrian hamster embryo cells containing different oncogenes.  VOL. 26. 1985
  • Kinetic studies of thymidine phosphorylase from mouse liver.  VOL. 26. 1985
  • Lower folic acid levels associated with bronchial metaplasia in smokers.  VOL. 26. 1985
  • Monoclonal antibodies defining B lineage specific Ia epitopes in malignant lymphoma.  VOL. 26. 1985
  • New inhibitors of dihydrouracil dehydrogenase.  VOL. 26. 1985
  • Preferential organ adhesion and invasion by B16 melanoma cells selected for differing metastatic colonization properties.  VOL. 26. 1985
  • Suppression of methylnitrosourea (MNU)-induced mammary cancers by pregnancy: Elimination of preneoplastic cells.  VOL. 26. 1985
  • Effect of age at time of 1-methyl-1-nitrosourea administration on mammary carcinogenesis.  Vol. 23. 1982
  • Exploitable mechanisms in cancer therapy.  Vol. 23. 1982
  • New inhibitors of the pyrimidine nucleoside phosphorylases.  Vol. 23. 1982
  • Alternative approaches to therapy after plateau in multiple myeloma.  Vol. 22. 1981
  • Antagonism between retinoids and phorbol esters.  Vol. 22:501. 1981
  • Benzyl acyclouridine, a new potent inhibitor of uridine phosphorylase.  Vol. 22:833. 1981
  • CAF vs. CMFVP in patients with advanced breast cancer.  Vol. 22. 1981
  • Effect of chemotherapeutic regimen on induction rate and survival in good risk non-Hodgkin's lymphoma (NHL).  Vol. 22. 1981
  • Phase III trial of CHOP vs BCOP in diffuse histiocytic lymphoma (DHL).  Vol. 22. 1981
  • Randomized comparison of cyclophosphamide (C), adriamycin (A), methotrexate (M) and folinic acid (F) vs cyclophosphamide, adriamycin and cis-platinum (P) vs cyclophosphamide and adriamycin in advanced non small cell lung cancer (NSCLC).  Vol. 22. 1981
  • Comparison of tumor induction by ethylnitrosourea and methylnitrosourea in a localized lung tumor model.  Vol. 20:389. 1979
  • Cyclophosphamide (C) plus DTIC (D) alone or with piperazinedione (P) in melanoma.  Vol. 20. 1979
  • Effect of piperazinedione (NSC 135758) and irradiation combined treatment on stem cell populations in normal and leukemic mice.  Vol. 20. 1979
  • Improving transplantation therapy of leukemia: A new model for testing marrow ablative pretreatments.  Vol. 20:341. 1979
  • Serum concentration of methotrexate (MTX) during high, intermediate and low dosage schedules.  Vol. 20. 1979
  • Comparison of cyclophosphamide (C) plus one day DTIC (D1) or five day DTIC (D5) in metastatic malignant melanoma (MM).  Vol. 19. 1978
  • Development of an in vitro assay of antineoplastic drug efficacy with tumor models.  Vol. 19. 1978
  • Induction of transitional cell carcinomas (TCC) with N-butyl-(4-hydroxybutyl)nitrosamine (OH-BBN) in female rats.  Vol. 19. 1978
  • Cyclophosphamide, adriamycin, methotrexate + folinic acid rescue (CAMFAR) treatment of metastatic adenocarcinoma of the lung.  Vol.18. 1977
  • Drug evaluation with experimental murine myeloma.  Vol. 18. 1977
  • Suppression of NMU induced mammary cancer by vitamin A acetate.  Vol.18. 1977
  • BCNU, cyclophosphamide, and prednisone (BCP) vs. melphalan and prednisone (MP) in myeloma.  Vol.17. 1976
  • Chemotherapy of multiple myeloma in experimental animals.  Vol. 17. 1976
  • Suppression of DMBA induced mammary tumorigenesis by retinyl methyl ether.  Vol. 17. 1976
  • The effect of BCG on remission duration and survival in acute myeloblastic leukemia.  vol. 17:435. 1976
  • Binding of light exposed benz(a)anthracene (BA) derivatives to glyceraldehyde 3 phosphate dehydrogenase (GPDH) and mammary tissue.  16. 1975
  • Effect of light on the reaction of glyceraldehyde 3 phosphate dehydrogenase with DMBA derivatives.  Vol. 15:53. 1974